5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
Recently, Aureka Biotechnologies, a Tech-Bio company focused on agent-driven antibody drug development, announced the completion of a $35 million Series A+ round. The round was led by HSG, with Matrix Partners China and BioTrack Capital participating, while existing investors 5Y Capital, Qiming Venture Partners, and New Alliance Capital continued their investment. To date, Aureka has raised nearly $100 million across its Series A and A+ rounds combined.
The proceeds will primarily fund the development of Aureka's self-built innovative functional antibody design platform, AuraIDE™, strengthening its foundation models and agent capabilities, and expanding its high-throughput, high-content experimental infrastructure. The company aims to further connect the critical stages of agent-driven drug development — from project initiation and molecular design to drug development and translational delivery — accelerating its diversified pipeline of innovative drugs toward clinical stages.
Building Tech-Bio Infrastructure for Scalable Antibody Design
Centered on the core challenge of de novo functional antibody design, Aureka is building customized high-throughput, high-content experimental infrastructure to support its generative antibody design system, improving the evolutionary efficiency of model and process iteration, and scaling the production of differentiated, high-value innovative functional antibodies.
By integrating high-throughput single-cell functional screening with synthetic biology evolution systems, Aureka is continuously reimagining how functional data is acquired, creating a data foundation that combines high throughput with high information density. This supports ongoing model learning and optimization, continuously expanding the models' generalization boundaries and directed optimization capabilities across complex targets, mechanisms, and indications. The company has strategically positioned itself across multiple high-value, high-challenge domains including multispecific antibodies (AURA083), agonist antibodies (AURA104, 105), high-efficiency endocytosis antibodies (AURA136), pH-switch antibodies (AURA053), and epitope-specific targeting antibodies (AURA010, 012, 014). One drug candidate is approaching clinical stage, two have entered IND-enabling development, and the company has attracted sustained attention and collaborative engagement from multiple global top-tier pharmaceutical companies.
Commercial Partnerships and R&D Progress Advancing in Parallel
Aureka continues to advance joint R&D programs with multiple multinational pharmaceutical companies, conducting in-depth collaborations around complex targets and functional mechanisms, and gradually evolving from project-based partnerships toward molecular-level value co-creation and transaction conversion.
Over the past two years, Aureka has achieved tens of millions of dollars in commercial revenue, continuously validating its R&D system's competitive advantages in complex molecular design and functional realization through ongoing deliverables. As multiple pipeline programs enter critical preclinical stages, the company is progressively establishing a translational pathway from molecular design and functional validation to external transactions, with commercial capabilities entering an accelerated release phase.
Dr. Weian Zhao, founder and CEO of Aureka, stated: "We stand at the edge of a new era for the biopharmaceutical industry. We are in awe of the pace of progress in our models. Aureka's latest agent platform, AuraIDE™, can now design antibody molecules with clinical-grade functional features from scratch: precise targeting of complex epitopes, controllable activation/inhibition, multispecific synergy, pH-switch responsiveness... These targets once considered 'undruggable' are being systematically conquered.
Next-generation Tech-Bio infrastructure is not a nice-to-have — it is a prerequisite for rewriting the rules of the industry. This financing will accelerate the construction of the world's first agent-experiment collaborative foundation for scalable de novo antibody design, making First-in-class no longer a matter of chance, but a repeatable, scalable, deliverable system capability."
Xutian Jing, Partner at 5Y Capital, commented: "The combination of the company's unique ultra-high-throughput wet-lab platform with globally leading model capabilities brings the potential to unlock entirely new pharmaceutical spaces across multiple antibody drug types. We believe this round of financing will help the company unlock more antibody R&D potential and advance more high-value drug assets."
About Aureka Biotechnologies
Aureka Biotechnologies is a global leader in the Tech-Bio field, redefining the boundaries of antibody discovery through its closed-loop agent platform, AuraIDE™. Founded in 2023, the company operates R&D centers and high-throughput experimental platforms in both China and the United States. Aureka is committed to creating next-generation, high-value antibody drugs for patients worldwide through scalable de novo innovative functional antibody design. By continuously reimagining how functional data is generated, the company has built a high-throughput, high-content experimental data flywheel that drives the co-evolution of models and experiments, forming differentiated antibody discovery and optimization capabilities to accelerate the development of high-value innovative drug pipelines. Since its founding, Aureka has collaborated with multiple multinational pharmaceutical companies, successfully delivered projects, achieved tens of millions of dollars in commercial revenue, and is progressively establishing a commercialization pathway from platform capability output to molecular value conversion.
5Y Capital seeks out, supports, and inspires lone entrepreneurs, providing support from the spiritual to all operational aspects.
We believe that if the you whom others see as crazy begins to be believed in, the world will become a different place.
BEIJING · SHANGHAI · SHENZHEN · HONG KONG
